Stock Ratings / Health Care / ZNTL / insiders

WHWK (28) ADCT (33) YARW (41) SION (38) ⌘ Pro Terminal →

Zentalis Pharmaceuticals Inc. (ZNTL) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Where is ZNTL trading relative to its 50-day, 200-day, and 52-week technical levels?

ZNTL last traded at $1.96 (-1.51% on volume of 1,332,601 shares), positioning the stock -33.56% below its 50-day simple moving average ($2.95) and -43.19% below its 200-day simple moving average ($3.45). Across its 52-week range of $1.21 to $6.95, ZNTL sits at the 13.1% percentile with a 14-day RSI of 31.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.72 to $2.20).

Q: Are ZNTL insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ZNTL leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$1.96 -1.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.95

Zentalis Pharmaceuticals Inc. (ZNTL) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $188.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ZNTL Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ZNTL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.96 (-1.51% 1D, market cap $188.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ZNTL ranks #554 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ZNTL compare to WHWK and ADCT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZNTL carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, WHWK (Whitehawk Therapeutics Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $188.1M) and ADCT (ADC Therapeutics SA) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $190.2M). Among the 5-stock peer group, ZNTL leads on earnings multiple (N/A) while SION leads on capital efficiency (-28.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ZNTL?

▼

Per ZNTL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001725160), Zentalis Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$137.1M in net income, and -$125.2M in free cash flow against $289.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.95 (-0.46%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZNTL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (39/100 Composite)

🔍 WHY ZNTL SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 13% of 52W Range • RSI-14 at 31.1 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$2.64-19.3% Next Q

Q2 (-2Q)

Grade D$2.13+3.8% Next Q

Q3 (-1Q)

Grade D$2.21-11.3% Next Q

Current

Grade D-$1.96-7.6% Hist 90D α

Trajectory: D (47) → D- (39)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZNTL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZNTL currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.95) and Max Pain ($2.06) forces dealer call-delta covering toward $7.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZNTL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ZNTL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 39%NO 61%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ZNTL Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ZNTL)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ZNTL. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZNTL)

✓Walkthrough of ZNTL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ZNTL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -51.12%▼ SUPPORT BREAKDOWN

2026-10-30O $1.99H $1.99L $1.86C $1.96VOL 1.33M

RES: $5.24SUP: $2.58SMA50: $2.95SMA200: $3.45

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZNTL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZNTL Butterfly Map → + Track ZNTL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ZNTL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZNTL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ZNTL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZNTL)

Health Care Rank #554 of 1016 ⚔️ WHWK vs ZNTL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZNTL vs. WHWK, ADCT, YARW, SION)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Zentalis Pharmaceuticals Inc. (ZNTL) ranks #554 by composite RQD confidence (39/100, grade D-) and #585 by equity capitalization ($188.4M). Within this direct 5-issuer industry benchmark cohort, ZNTL leads on earnings valuation at N/A trailing P/E, while SION leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. YARW currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with ZNTL at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ZNTL ACTIVE Zentalis Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	-1.51%	$188.4M	Benchmark Subject
WHWK Whitehawk Therapeutics Inc.	E	28/100	—	89.4%	-35.0%	-1.82%	$188.1M	/whwk-vs-zntl →
ADCT ADC Therapeutics SA	E	33/100	—	92.9%	-35.0%	+2.69%	$190.2M	/adct-vs-zntl →
YARW Yarrow Bioscience Inc.	D-	41/100	—	—	-35.0%	-0.50%	$186.1M	/yarw-vs-zntl →
SION Sionna Therapeutics Inc.	D-	38/100	—	—	-28.3%	-3.25%	$180.8M	/sion-vs-zntl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001725160

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zentalis Pharmaceuticals Inc. (ZNTL) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $67.4M ) , GAAP net income of -$137.1M, operating cash flow of -$125.2M, and free cash flow of -$125.2M (+26.8% YoY). On the balance sheet, ZNTL closed FY2025 with $289.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$137.1M	-$125.2M	-$125.2M	$289.0M	—
FY2024 (FY)	2024-12-31	$67.4M	-$165.9M	-$170.9M	-$171.1M	$430.3M	—
FY2023 (FY)	2023-12-31	$0	-$292.3M	-$207.8M	-$207.8M	—	—

3. ZNTL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZNTL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ZNTL compare to WHWK and ADCT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ZNTL?

Where is ZNTL trading relative to its 50-day, 200-day, and 52-week technical levels?

ZNTL last traded at $1.96 (-1.51% on volume of 1,332,601 shares), positioning the stock -33.56% below its 50-day simple moving average ($2.95) and -43.19% below its 200-day simple moving average ($3.45). Across its 52-week range of $1.21 to $6.95, ZNTL sits at the 13.1% percentile with a 14-day RSI of 31.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.72 to $2.20).

ZNTL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are ZNTL insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ZNTL leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: ZNTL RQD Cockpit ZNTL 12M Forecast ZNTL Earnings & Move ZNTL Dividends & DRIP ZNTL Insiders & 13F ZNTL Whale Options ZNTL Profit Sankey ZNTL News & Why

ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ZNTL — Zentalis Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:41:36Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ZNTL scores 39 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow."

Fundamental Cash Engine (8 / 20): Per the Roarable RQD rating, ROIC is -35% and FCF yield is 0%. The SEC financials show net losses in each reported fiscal year, so the operating business is not currently generating cash to support the valuation. Upside here depends on a future turnaround that the source data does not demonstrate.
Whale / 13F Flow (6 / 20): Per the Roarable RQD rating, institutional accumulation and options positioning score weakly. The holders section contains only a passive-stake reference in the news wire, so institutional support is limited in the source data.
Insider Conviction (5 / 20): Per the Roarable RQD rating, SEC Form 4 and Congressional PTR cluster flow score weakly. Insider signaling is not a source of conviction in this dataset.
Macro Regime Fit (10 / 20): Per the Roarable RQD rating, beta is 1.0 and sector sensitivity is moderate. The stock is not positioned as a defensive holding relative to market swings.
Forensic Balance Sheet (10 / 20): Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. These readings signal financial strain rather than strength.

For a prospective investor evaluating the stock today, the rating frames ZNTL as a high-risk setup: the upside case rests on pipeline or catalyst outcomes outside the reported financials, while the downside case rests on continued cash burn and weak flow signals. Valuation tradeoffs are difficult to assess because earnings-based multiples are not available in the source data.

Business

Zentalis Pharmaceuticals Inc. (ZNTL) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $0.2B. Per the SEC financials, FY 2024 revenue was $67.4M, while FY 2025 and FY 2023 revenue were $0.0M. Not available in source data for detailed product descriptions, customer segments, or revenue model.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-152.8M	$-137.1M	N/A	$-125.2M	$36.0M	N/A
FY 2024	$67.4M	$-191.2M	$-165.9M	N/A	$-171.1M	$33.9M	N/A
FY 2023	$0.0M	$-299.5M	$-292.3M	N/A	$-207.8M	N/A	N/A

Per the SEC financials, the company reported operating and net losses across all three periods, and margins per the market data are 0% for gross, operating, and net. Per the Roarable RQD rating, ROIC is -35%. Per the Roarable RQD rating, Altman Z-Score is 2.5, Piotroski F-Score is 3/9, and Debt/Equity is 0.5. The balance sheet posture is weak on flow metrics despite the moderate Altman reading.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section:

Catalyst (GREEN): A Yahoo Finance report describes shares rising after Leerink assumed coverage with an Outperform rating.
Market wire (YELLOW): Seeking Alpha reports shares rising on cancer trial data.
Market wire (YELLOW): TradingView, GuruFocus, and Stock Titan items cover market action and a passive stake update showing BlackRock sole voting power over 3.80M shares.
Market wire (YELLOW): HC Wainwright & Co. reiterated a Buy rating with a $10 price target.

Per the Butterfly Supply-Chain Graph, supply chain is NONE, with no butterfly links and no proprietary signals.

Open Questions

What are the specific trial outcomes referenced in the cancer trial data coverage, and what is the timing of further readouts?
What are the drivers of the FY 2024 revenue of $67.4M, and why is revenue zero in FY 2025?
What is the company's cash runway given FY 2025 cash of $36.0M against FCF of $-125.2M?
Why are EPS and debt values unavailable in the financials, and what is the debt structure?
What is the breakdown of the 13F institutional holdings and insider activity beyond the single passive stake reference?

ZNTL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Zentalis Pharmaceuticals Inc. (ZNTL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ZNTL Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 6h ago

Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating

Yahoo Finance report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 9h ago

Zentalis stock rises on cancer trial data (ZNTL:NASDAQ)

Seeking Alpha report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 12h ago

Zentalis Pharmaceuticals, Inc. Estimates – NASDAQ:ZNTL

TradingView report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 15h ago

Zentalis Pharmaceuticals (ZNTL) Shares Rise After Positive Mid-S

GuruFocus report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 18h ago

BlackRock reports sole voting power over 3.80M Zentalis (ZNTL) shares in a passive stake update.

Stock Titan report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 21h ago

HC Wainwright & Co. reiterates Buy rating on Zentalis Pharmaceuticals, $10 price target

TradingView report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Zentalis published survival data for Zentalis Pharmaceuticals stock

ad-hoc-news.de report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

ZNTL Q2 2026 Earnings: Wider-Than-Expected Loss Highlights Spending Discipline Challenge - Cost Structure Review

https://www.dars.gov.et/ report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ZNTL Bull vs. Bear Conversation Board — What's Your Call at $1.96?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZNTL 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.72 (-12.2%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ZNTL (D- • RQD 39/100) a Buy at $1.96?

Welcome to the ZNTL (Zentalis Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.59 (-18.9%)

Spot @ $1.96

Pump the brakes on ZNTL — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ZNTL, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Zentalis Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.29 (+16.8%)

Spot @ $1.96

ZNTL cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ZNTL, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.96 (52-wk range $1.21 - $6.95), any beat on forward guidance forces shorts and underweight funds to chase.